Quantum BioPharma Announces Debt Settlement, Equity Grants, and Advisor Departure
Quantum BioPharma has settled outstanding debt through share issuance, granted restricted share units tied to regulatory milestones for its Lucid MS program, and terminated an advisor agreement, reflecting strategic financial and clinical development moves.
